Retrophin (RTRX) Tops Q2 EPS by 16c

Retrophin (NASDAQ: RTRX) reported Q2 EPS of ($0.07), $0.16 better than the analyst estimate of ($0.23). Revenue for the quarter came in at $33.3 million versus the consensus estimate of $32.73 million.

“We are very pleased with our strong second quarter performance, which was led by growth across all of our commercial products, and included the expansion of our pipeline,” said Stephen Aselage, chief executive officer of Retrophin. “We look forward to building upon the momentum from the first half of the year with upcoming clinical milestones for sparsentan and RE-024, which we believe will make 2016 a transformational year for Retrophin.”

As of June 30, 2016, the Company had cash, cash equivalents, marketable securities and notes receivable of $315.2 million.

For earnings history and earnings-related data on Retrophin (RTRX) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Tvardi Therapeutics (TVRD) Tops Q2 EPS by 1c
• Movano (MOVE) Misses Q2 EPS by 195c